News

The prognostic value of minimal residual disease negativity in multiple myeloma may make it a suitable surrogate endpoint in clinical trials, according to a group of researchers.

The data showed that a daily intake of around 300 IU of vitamin D — roughly the same as three 8-oz. glasses of milk — was linked to a nearly 50% decreased risk of early-onset colorectal cancer among women between the ages of 25 and 42 years.

Nagla Abdel Karim, MD, explains how researchers will address safety and manage potential adverse events in the ongoing phase 3 CheckMate-73L trial.

Over half of the states in the United States have legalized medical cannabis. What does that mean for nurses who care for patients with cancer?

Multidisciplinary approaches are still needed to proactively address the high relapse rates in patients with ovarian cancer treated with platinum-based chemotherapies, says Sanaz Memarzadeh, MD, PhD.

Zanubrutinib (Brukinsa) is now FDA approved for the treatment of adults with Waldenström Macroglobulinemia.

Adherence to current clinical guidelines may contribute to systematic underdiagnosis in Black women, says Kemi M. Doll, MD, MS.

“It’s a Privilege, I feel very honored to be helping patients.”

A seroconversion rate of 94% was identified in a diverse cohort of patients with cancer who had received the COVID-19 vaccine.

Pembrolizumab has been granted full approval as a first-line treatment for a select population of patients with bladder cancer.

Newly standardized grading criteria will help to regulate the management of CAR T-cell therapy¬–related toxicities, like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Kelly Garvin, BSN, RN, OCN, discusses the impact of CAR T-cell therapy on patients and how nurses care for them, as well as her expectations on how indications will grow.

Increases were detected in all cancer screening procedures except for colonoscopies.

As patients with hematologic cancers live for normal life expectancies, the consequences associated with opioid use becomes more severe.

An official statement has been signed and issued by the National Comprehensive Cancer Center Network insisting that health care systems mandate COVID-19 immunizations for their workers

Identifying targets early can help forestall resistance and improve the efficacy of osimertinib, a EGFR tyrosine kinase inhibitor, in the first-line setting.

Tisagenlecleucel is a CAR T-cell therapy approved to treat follicular lymphoma that has minimal toxicity and is safe in the outpatient setting.

Small employment increases in March and February didn’t replenish the more than 80,000 jobs lost in January.

“There were delays in getting preventative screenings, there were delay in diagnostics, there was also a brief period of time when some of the clinical trials were shut down.”

The FDA approved ivosidenib as the first targeted therapy to treat patients with previously treated IDH1-mutated cholangiocarcinoma.

While disparities exist in screening accessibility among the Hispanic/Latinx communities, the implementation of interventions have shown promising results in increased clinical trial participation.

The FDA’s priority review designation to abatacept may help to expand the stem cell donor pool by lowering acute graft-versus-host-disease risk in both children and adults, experts say.

The Food and Drug Administration approved adjuvant nivolumab to treat urothelial carcinoma in patients who are at high risk of recurrence after undergoing radical resection, irrespective of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.

The new Oncology Medical Home standards represent a universal benchmark in a value-based model of oncology care.

Kelly L. Garvin, BSN, RN, OCN, discusses what changes she hopes to see in CAR T-Cell therapy treatment over the coming years.

The regulatory decision is based on findings from collective data from the dMMR endometrial cancer cohort A1 and the dMMR solid-tumor, non-endometrial cancer, cohort F of the ongoing phase 1 GARNET trial (NCT02715284).

Patients with non-small cell lung cancer driver mutations respond better to targeted treatments compared to chemotherapy, yet less than half of these patients receive next generation sequencing.

The continued development of KRAS G12C inhibitors for the treatment of non-small cell lung cancer shows that researchers are making breakthroughs in the treatment landscape.

Belzutifan, a hypoxia-inducible factor inhibitor, has been approved for treatment of adults with cancers related to von Hippel-Lindau disease.

The combination of pembrolizumab and lenvatinib has been FDA approved as a frontline therapy for the treatment of adult patients with advanced renal cell carcinoma.